Kiniksa Pharma Files 2025 Proxy Statement

TL;DR

Kiniksa Pharma dropped its 2025 proxy statement, shareholders vote soon.

AI Summary

Kiniksa Pharmaceuticals International, plc filed a Definitive Proxy Statement (DEFA14A) on May 28, 2025, for its 2025 Annual Meeting of Shareholders. The filing details the company's proxy materials, which are used to solicit shareholder votes on various corporate matters. The company is based in London and operates in the pharmaceutical preparations industry.

Why It Matters

This filing is crucial for shareholders as it outlines the agenda for the annual meeting and provides information needed to make informed voting decisions on company matters.

Risk Assessment

Risk Level: low — This is a routine proxy filing and does not contain new financial information or significant corporate actions that would inherently increase risk.

Key Players & Entities

• Kiniksa Pharmaceuticals International, plc (company) — Registrant
• 2025 Annual Meeting of Shareholders (event) — Subject of the proxy statement
• May 28, 2025 (date) — Filing date
• London (location) — Company headquarters

FAQ

From the Filing

0001104659-25-053649.txt : 20250528 0001104659-25-053649.hdr.sgml : 20250528 20250528172319 ACCESSION NUMBER: 0001104659-25-053649 CONFORMED SUBMISSION TYPE: DEFA14A PUBLIC DOCUMENT COUNT: 3 FILED AS OF DATE: 20250528 DATE AS OF CHANGE: 20250528 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Kiniksa Pharmaceuticals International, plc CENTRAL INDEX KEY: 0001730430 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: DEFA14A SEC ACT: 1934 Act SEC FILE NUMBER: 001-38492 FILM NUMBER: 25996603 BUSINESS ADDRESS: STREET 1: 23 OLD BOND STREET, FLOOR 3 CITY: LONDON STATE: X0 ZIP: WIS 4PZ BUSINESS PHONE: 7814319100 MAIL ADDRESS: STREET 1: 23 OLD BOND STREET, FLOOR 3 CITY: LONDON STATE: X0 ZIP: WIS 4PZ FORMER COMPANY: FORMER CONFORMED NAME: Kiniksa Pharmaceuticals, Ltd. DATE OF NAME CHANGE: 20180205 DEFA14A 1 tm2516398d1_defa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy Statement x Definitive Additional Materials ¨ Soliciting Material under §240.14a-12 KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): x No fee required. ¨ Fee paid previously with preliminary materials. ¨ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 Supplement to the Definitive Proxy Statement For the 2025 Annual Meeting of Shareholders to be Held on June 3, 2025 May 28, 2025 Dear Shareholder: By now you should have received Kiniksa Pharmaceutical International, plc’s ( the “ Company ”, “ we ,” “ us ,” or “ our ” ) Proxy Statement, along with the proxy card or notice of Internet availability of proxy materials related to our Annual Meeting of Shareholders to be held on June 3, 2025 at 3:00 p.m. British Summer Time (10:00 a.m. Eastern Daylight Time) at Third Floor, 23 Old Bond Street, London, United Kingdom W1S 4PZ (the “ Annual Meeting ”). We have asked for your support of our Board of Director’s recommendations on the proposals to be voted on at the Annual Meeting. In this letter, we specifically focus on two proposals that seek to address limitations on UK-domiciled companies that would not apply to Delaware or other US-domiciled companies, in light of the recommendation to vote “Against” such proposals by Institutional Shareholder Services (“ ISS ”). Glass Lewis and Egan Jones, other prominent proxy advisory firms, have recommended shareholders vote “For” the Share Authority Proposals. As further described in the Proxy Statement, pursuant to the UK Companies Act of 2006 (the “ Companies Act ”), our Board of Directors must have specific authority from shareholders to allot shares in the Company or to grant rights to subscribe for or to convert any security into shares in the Company. Additionally, the Companies Act requires that where we wish to issue shares for cash, we must first offer those shares on the same terms to existing shareholders of the Company on a pro-rata basis (commonly referred to as a statutory pre-emption right) unless this statutory pre-emption right is dis-applied, or opted-out of, with the approval of our shareholders. Proposal 11 seeks authority to allot shares up to approximately 35% of the issued ordinary share capital of the Company (with such authority expi